Stupnicki T, Taufer M, Denk H, Ratschek M, Spath P, Graf K
Department of Internal Medicine, General Hospital Deutschlandsberg, Austria.
Aliment Pharmacol Ther. 1996 Apr;10(2):193-7. doi: 10.1046/j.1365-2036.1996.720100000.x.
Seventy-seven chronic duodenal ulcer patients (50 male) were entered into this study. Treatment was started with sucralfate suspension (2 g b.d.) for 8 weeks. After 2 weeks the patients also received 750 mg amoxycillin t.d.s. plus 500 mg metronidazole t.d.s. for 12 days. Endoscopy with six antral biopsies (urease test, Gram staining, culture and histology) was performed before commencement of sucralfate therapy, 4 weeks after the end of antibiotic therapy, and during the follow-up examinations at 6 and 12 months.
Seven patients were excluded prematurely from the study. Helicobacter pylori in five patients had primary resistance to metronidazole and these patients were also excluded. The ulcer healing rate 4 weeks after the end of antibiotic therapy was 92% and the H. pylori eradication rate was 82% (all per protocol). In all patients who were still H. pylori-positive, the bacterium became resistant to metronidazole and histologically the inflammatory state of the mucosa was the same as before treatment. All H. pylori-eradicated patients (n = 53) were re-examined after 6 and 12 months; no ulcer recurrence was observed and each time only one reinfection was found.
In an open study, sucralfate with amoxycillin and metronidazole appeared to act together to eradicate H. pylori infection and to speed duodenal ulcer healing.
77例慢性十二指肠溃疡患者(50例男性)进入本研究。治疗开始时给予硫糖铝混悬液(每日2次,每次2 g),持续8周。2周后,患者还接受阿莫西林750 mg每日3次加甲硝唑500 mg每日3次,共12天。在硫糖铝治疗开始前、抗生素治疗结束后4周以及6个月和12个月的随访检查期间,进行内镜检查并取6块胃窦活检组织(尿素酶试验、革兰氏染色、培养和组织学检查)。
7例患者被提前排除出研究。5例患者的幽门螺杆菌对甲硝唑原发耐药,这些患者也被排除。抗生素治疗结束后4周的溃疡愈合率为92%,幽门螺杆菌根除率为82%(均按方案计算)。在所有仍为幽门螺杆菌阳性的患者中,该菌对甲硝唑产生耐药,并且从组织学上看,黏膜的炎症状态与治疗前相同。所有幽门螺杆菌根除的患者(n = 53)在6个月和12个月后进行复查;未观察到溃疡复发,每次仅发现1例再次感染。
在一项开放性研究中,硫糖铝联合阿莫西林和甲硝唑似乎共同作用以根除幽门螺杆菌感染并加速十二指肠溃疡愈合。